JPMorgan analyst Brian Cheng placed Roivant Sciences (ROIV) on “Positive Catalyst Watch” while keeping an Overweight rating on the shares with a $16 price target The firm expects brepocitinib’s pivotal readout in dermatomyositis to occur in the early part of the back half of the year. It believes brepocitinib’s mechanism of action is already de-risked based on published case studies. JPMogan thinks the drug will become the preferred JAKi in a major portion of the dermatomyositis market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Roivant Sciences resumed with a Buy at Goldman Sachs
- Roivant Sciences participates in a conference call with JPMorgan
- Roivant Sciences Announces $500M Share Repurchase Program
- Roivant Sciences announces $500M share repurchase program
- Optimistic Outlook for Roivant Sciences: Buy Rating Backed by Brepo’s Potential and Financial Opportunities